Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV Tscm-CTL Therapy for EBV-Driven Lymphomas and Diseases
NCT05688241Phase 2Not yet recruiting
- Sponsor
- University Hospital Basel
- Start
- Nov 2026
- Primary completion
- Dec 2031
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of epstein-barr virus-specific stem cell memory cytotoxic T lymphocytes in Epstein-Barr virus-associated lymphoma, Post-transplant lymphoproliferative disease (PTLD), hemophagocytic lymphohistiocytosis (HLH), chronic active Epstein-Barr virus infection (CAEBV), sponsored by University Hospital Basel. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
epstein-barr virus-specific stem cell memory cytotoxic T lymphocytes
03
Conditions
Epstein-Barr virus-associated lymphomaPost-transplant lymphoproliferative disease (PTLD)hemophagocytic lymphohistiocytosis (HLH)chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT05688241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05688241.